In breast cancer, more than 40% of HR+ cases carry PIK3CA mutations, leading to hyperactive PI3K signaling that promotes tumor growth. Advances in genetic testing—like next-generation sequencing—make it easier to identify patients with these mutations, paving the way for physicians to provide more personalized care. Learn more from Katherine Ansley, Clinical Associate Professor of Hematology and Oncology at Wake Forest University School of Medicine: http://spr.ly/6049055y7
The PI3K Pathway In Breast Cancer
Great works
Scott McLean
6d
Fascinating!!
A promising new era for breast cancer care: protein degraders targeting PI3K mutations could offer safer, more durable treatments for patients. A major step forward in precision oncology.
Crista Cody
4d
So interesting! Great work, Dr Ansley!
Global cancer PT expert, podcaster, educator, program builder and Explainer in Chief. Collabs with the World Health Organization, the American Cancer Society, the APTA and CURE Magazine.
1wFabulous work, Dr. Ansley!!!